Clinical Trials Logo

Clinical Trial Summary

This is the 4th LMB study by the French African Pediatric Oncology Group (GFAOP). The study hopes to be able to evaluate children earlier with stage I and II disease and to evaluate treatment response earlier so that the units can decide if a change in treatment is necessary, it is also hoped to provide an intensification of treatment for the stage IV disease.


Clinical Trial Description

This is the 4th Burkitt's Lymphoma (LMB) study by the GFAOP group. This study hopes to include at least 14 Sub Saharian countries some of whom have never participated in a LMB study. The evaluation of improvement in early diagnosis should be possible in this study. The study hopes to be able to evaluate children earlier, with stage I and II disease and to evaluate treatment response earlier so that the units can decide if a change in treatment is necessary, it is also hoped to provide an intensification of treatment for children with a stage IV disease. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04425421
Study type Observational
Source French Africa Pediatric Oncology Group
Contact Chantal Ms BOUDA, Dr.
Phone 00(226)70 10 01 30
Email cgbouda@yahoo.fr
Status Recruiting
Phase
Start date November 1, 2020
Completion date October 2026

See also
  Status Clinical Trial Phase
Completed NCT01943682 - Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma Phase 1
Completed NCT01093586 - Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Phase 2
Recruiting NCT05020392 - Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma Phase 3
Recruiting NCT04545762 - Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma Phase 1
Terminated NCT03864419 - Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda Phase 1
Terminated NCT02700022 - A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas Phase 1
Completed NCT00849147 - Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603) Phase 2
Completed NCT00822432 - Coproporphyrine Isomers and Methotrexate Elimination N/A
Recruiting NCT00180882 - LMBA02 Protocol for Patients With a Burkitt Lymphoma Phase 3
Recruiting NCT06060782 - Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine Phase 1
Active, not recruiting NCT02996773 - Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine Phase 1
Recruiting NCT05565417 - Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas Phase 1/Phase 2
Not yet recruiting NCT03298828 - CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma Phase 1
Completed NCT01290120 - Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma Phase 2
Active, not recruiting NCT00719888 - Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease Phase 2
Recruiting NCT06131801 - Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Completed NCT00001337 - Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma Phase 2
Recruiting NCT05518383 - B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 Phase 4
Terminated NCT01028716 - Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Phase 2
Recruiting NCT05794880 - MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing N/A